Inhibiting the conversion of soluble amyloid-β peptide into abnormally folded amyloidogenic intermediates: Relevance for Alzheimer's disease therapy

Acta Neurologica Scandinavica, Supplement

Volumn 102, Issue 176, 2000, Pages 90-95

  Soto, C ^a   Saborio, G P ^a   Permanne, B ^a  

^a SERONO PHARMACEUTICAL RES INSTITUTE   (Switzerland)

Author keywords

Alzheimer's disease; Amyloid; Protein conformational disorders; Therapy

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BETA SHEET BREAKER PEPTIDE; OLIGOMER; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BETA SHEET; CONTROLLED STUDY; DRUG STRUCTURE; DRUG SYNTHESIS; GENETIC ENGINEERING; MOLECULAR STABILITY; NONHUMAN; PATHOGENESIS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN FOLDING; RAT; SENILE PLAQUE; ANIMAL; BRAIN; CULTURE TECHNIQUE; DISEASE MODEL; HUMAN; METABOLISM; NEUROFILAMENT; PATHOLOGY; PATHOPHYSIOLOGY; PROTEIN SECONDARY STRUCTURE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; BRAIN; CELL CULTURE TECHNIQUES; DISEASE MODELS, ANIMAL; HUMANS; NEUROFIBRILS; PROTEIN STRUCTURE, SECONDARY; RATS; SENILE PLAQUES;

EID: 0034486603     PISSN: 00651427     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Cell biology of the amyloid beta-protein precursor and the mechanism of Alzheimer's disease
2. Neuropathological changes in Alzheimer disease
3. Amyloid deposition as the central event in the aetiology of Alzheimer's disease
4. Neuroscience - Alzheimer's disease: Genotypes, phenotype, and treatments
5. Structural determinants of the Alzheimer's amyloid beta-peptide
6. Structural and kinetic features of amyloid betaprotein fibrillogenesis
7. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: Implications for the pathogenesis of Alzheimer's disease
8. Substitutions of hydrophobic amino acids reduce the amyloidogenicity of Alzheimer's disease βA4 peptides
9. The alpha-helical to beta-strand transition in the amino-terminal fragment of the amyloid beta-peptide modulates amyloid formation
10. Prolines and amyloidogenicity in fragments of the Alzheimer's peptide β/A4
11. Arrest of βamyloid fibril formation by a pentapeptide ligand
12. The influence of the central region containing residues 19-25 on the aggregation properties and secondary structure of Alzheimer's beta-amyloid peptide
13. The molecular genetics of Alzheimer's disease
14. 21 to Gly on the aggregation of a synthetic fragment of the Alzheimer's amyloid β/A4 peptide
15. Alzheimer's and prion diseases as protein conformational disorders: Design of a novel therapeutic approach
16. Solution conformations and aggregational properties of synthetic amyloid beta-peptides of Alzheimer's disease. Analysis of circular dichroism spectra
17. The conformation of Alzheimer's β peptide determines the rate of amyloid formation and its resistance to proteolysis
18. Fractionation and characterization of oligomeric, protofibrillar and fibrillar forms of β-amyloid peptide
19. Amyloid betaprotein fibrillogenesis. Structure and biological activity of protofibrillar intermediates
20. Diffusible, nonfibrillar ligands derived from Abetal-42 are potent central nervous system neurotoxins
21. Mechanisms of neuronal degeneration in Alzheimer's disease
22. Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain
23. β-amyloid disrupting drugs: Potential in the treatment of Alzheimer's disease
24. Nicotine inhibits amyloid formation by the β-peptide
25. Inhibition of Alzheimer β-fibrillogenesis by melatonin
26. An analysis of side chain interactions and pair correlations within antiparallel betasheets: The differences between backbone hydrogen-bonded and non-hydrogen bonded residue pairs
27. Inhibition of Alzheimer's amyloidosis by peptides that prevent β-sheet conformation
28. β-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for Alzheimer's therapy
29. In vivo reversal of amyloid-β lesions in Rat brain
30. Conformational disease
31. Reversion of prion protein conformational changes by synthetic β-sheet breaker peptides